Skip to content
EntityQ409697· pop 16· linked from 67 articles

ペグビソマント

Sign in to save

Also known as GH-N, Growth hormone, GH, Pituitary growth hormone, Somatotropin precursor, Growth hormone 1, B2036-PEG

Pegvisomant, sold under the brand name Somavert, is a growth hormone receptor antagonist used in the treatment of acromegaly. It is primarily used if the pituitary gland tumor causing the acromegaly cannot be controlled with surgery or radiation, and the use of somatostatin analogues is unsuccessful, but is also effective as a monotherapy. It is delivered as a powder that is mixed with water and injected under the skin.

Chemical data

Drug data · ChEMBL

Max clinical phase
Approved
Molecule type
Protein
First approval
2002
Admin. routes
parenteral
Indications
acromegaly, prostate adenocarcinoma, sarcoma, breast neoplasm

via ChEMBL · EBI

Wikidata facts

Has use
medication
Show 3 more facts
medical condition treated
acromegaly
defined daily dose
10.0
has characteristic
biopharmaceutical
Sources (4)

via Wikidata · CC0

Article · 日本語

ペグビソマント(Pegvisomant)は、先端巨大症の治療に使用される成長ホルモン受容体拮抗薬である。先端巨大症の原因である下垂体腫瘍を手術や放射線治療で制御できない場合に使用される。主にソマトスタチンアナログの使用で効果が得られない場合に用いられるが、単剤投与でも有効である。皮下注射で投与される。

Abstract from DBpedia / Wikipedia · CC BY-SA